Ligand Pharmaceuticals (LGND) Could Be 9% Undervalued Following Buy Rated Earnings Strength
Fresh commentary around Ligand Pharmaceuticals (LGND), including a reiterated Buy rating from Bank of America Securities and reports of higher quarterly revenue and net profit versus last year, has pushed this stock back into focus.
At a share price of $314.78, Ligand Pharmaceuticals has seen short term momentum build, with a 1 day share price return of 2.73% feeding into a 7 day move of 6.71% and a 30 day gain of 8.52%. A 1 year total shareholder return of 69.63% and a very large 3 year total shareholder return of more than 5x suggest that the recent analyst commentary and higher reported quarterly revenue and net profit are being interpreted as signs of improving prospects rather than rising risk.
Scan beyond Ligand Pharmaceuticals and see which other drug developers are showing similar momentum and analyst conviction with the hand picked 21 high quality undiscovered gems.
After a run like this and a price near recent analyst targets, the core question around Ligand Pharmaceuticals is straightforward: Does the current valuation still leave enough upside to justify the risk buyers are taking on now?
Most Popular Narrative: 9% Undervalued
On the most followed view of Ligand Pharmaceuticals, a fair value of $344.25 sits ahead of the latest $314.78 close, so the market is treating that narrative as only partly priced in.
Expansion of Ligand Pharmaceuticals’ high margin royalty portfolio through the completed XOMA Royalty acquisition, which adds more than 120 assets including additional commercial products and late stage programs, is expected to widen the base of recurring royalty revenue and support higher earnings power as the assets mature.
See why 6 investors see Ligand Pharmaceuticals as 9% undervalued.
Result: Fair Value of $344.25 (UNDERVALUED)
Still, the bullish case for Ligand Pharmaceuticals depends on partners executing cleanly. As a result, any regulatory setbacks or drug pricing pressure could quickly challenge this valuation story.
Find out about the key risks to this Ligand Pharmaceuticals narrative.
Another Angle On Ligand Pharmaceuticals: Rich Multiple, Different Message
Through the lens of earnings multiples, Ligand Pharmaceuticals screens very differently. The stock trades on a P/E of 31.8x, while the fair ratio sits at 22.5x and peers are closer to 21.5x, with the wider US Pharmaceuticals group around 15.7x. That gap points to real valuation risk if enthusiasm cools even slightly.
For anyone weighing these multiples against the earlier fair value narrative, the key question is simple: Does the quality of Ligand Pharmaceuticals justify paying so far above both peers and that fair ratio, or is this where discipline needs to kick in? See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals on Ligand Pharmaceuticals so far. If you want to move fast and reach your own call on risk and reward, start with the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Ligand Pharmaceuticals?
Do not stop with one ticker. Broaden your watchlist with fresh ideas that match your risk, income, and quality goals, and let the data do the heavy lifting.
- Chase calculated upside by scanning a curated 33 high quality undervalued stocks that filters for quality businesses trading below their assessed worth.
- Build a steadier income stream by reviewing a hand picked mix of 7 dividend fortresses that focus on yield and resilience together.
- Protect your capital first by zeroing in on 31 resilient stocks with low risk scores that emphasise robust balance sheets and lower overall risk profiles.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com